Business Wire

Knopp Biosciences Presents Positive Preclinical Data for Lead Neonatal Epilepsy Drug Candidate at 2019 Antiepileptic Drug and Device Trials XV Conference

Share

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need, today presented in vitro and in vivo data for the company’s lead molecule for the targeted treatment of KCNQ2-neonatal epileptic encephalopathy (KCNQ2-NEE) at the Antiepileptic Drug and Device Trials XV Conference in Miami, Florida. KCNQ2-NEE, a rare infant genetic epilepsy, results from mutations in genes encoding the Kv7.2/Kv7.3 ion channel, leading to frequent seizures and profound developmental delay.

The preclinical data were presented by Steven Dworetzky, Ph.D., Knopp’s Chief Scientific Officer, a longtime Kv7 researcher who led the group that first cloned the Kv7.2 and Kv7.3 genes during his former tenure with the Bristol-Myers Squibb Co. Dr. Dworetzky presented results demonstrating the in vitro nanomolar activity of KB-3061 and its significant seizure protection in the maximal electroshock model (MES) of epilepsy. In addition, in vivo tolerability was demonstrated by the absence of an effect on neurological score at doses that conferred full protection. KB-3061 is differentiated from other molecules in its class, including ezogabine, which was also tested in the in vitro and in vivo models. Among the highlights:

  • In the MES model, KB-3061 protected rats from seizures at a dose more than 20 times lower than the dose of ezogabine required to achieve equivalent seizure protection and also showed significantly greater tolerability.
  • KB-3061 did not increase the activity of GABA in an allosteric GABAA receptor assay.
  • KB-3061 was chemically stable in a standard photooxidation assay.

“Knopp is very encouraged by the in vitro profile and in vivo profile of KB-3061,” Dr. Dworetzky said. “Children with KCNQ2-NEE and their families urgently need precision medicines with the potential to restore ion channel function and change the course of this disease.”

Knopp is conducting preclinical toxicology studies of KB-3061 in advance of submitting an Investigational New Drug Application to the Food and Drug Administration to initiate clinical trials.

Ion channels are proteins that regulate the excitability of cells. Drugs that modulate ion channels play an important role in treating a variety of neurological, cardiovascular, and smooth muscle conditions. Among ion channel targets, potassium channels play a key role in the pathophysiology of epilepsy and other diseases of high unmet need in the nervous system. Knopp is advancing a library of Kv7.2/7.3 channel activators to modulate this key ion channel in excitable cells, targeting not only the devastating genetic mutation associated with neonatal encephalopathy, but also other rare epilepsies and neuropathic pain.

Knopp's Kv7 research is supported under Award Number U44NS093160 of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH). The content of this announcement is solely the responsibility of Knopp and does not necessarily represent the views of the NIH.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 development in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, and neuropathic pain. Please visit www.knoppbio.com.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Media:
James Heins
james.heins@icrinc.com
646-277-8251

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mary Kay Reveals Breakthrough Anti-Gravity Findings at the 49th European Society for Dermatological Research Meeting18.9.2019 09:00:00 EESTPress release

Mary Kay Inc., a leader in skin care innovation, continues its decades-long commitment to skin science by sharing its latest research targeting the causes and underlying mechanisms of slackened skin at the 49th Annual Meeting of the European Society for Dermatological Research (ESDR) held on September 18-21 in Bordeaux, France. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917006232/en/ By uniting the finest specialists of European dermatology under the umbrella theme “Connecting Skin Science and Health,” the 49th ESDR meeting provides a unique opportunity for Mary Kay to share its latest technological advances and breakthroughs on skin health. The appearance of slackened, sagging skin tends to become prevalent in the fourth or fifth decade of life regardless of lifestyle or environmental exposure. The constant effect of gravity over time contributes to the emergence of prominent nasolabial folds and sagging skin along t

ASICS Named Official Footwear and Apparel Partner of the Mouratoglou Academy18.9.2019 08:30:00 EESTPress release

ASICS has today announced it will become the official tennis footwear and apparel partner of the prestigious Mouratoglou Academy, as part of a multi-year deal. Founded in 1996 by Patrick Mouratoglou, the academy has seen some of the world’s best talents in the game of tennis hone their skills at the world-class facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917006141/en/ ASICS has today announced it will become the official tennis footwear and apparel partner of the prestigious Mouratoglou Academy. Pictured (L-R): Patrick Mouratoglou, Founder and President, Mouratoglou Academy; Gary Raucher, Vice President Product and Marketing, ASICS (Photo: Business Wire) Speaking about the partnership, Founder and President Patrick Mouratoglou said: “I’m thrilled to partner with ASICS. They are not only a brand with a strong reputation of having the most technologically advanced tennis shoes on the market, but they also belie

Shiseido Marks the 30th Anniversary of Joint Research in Dermatology18.9.2019 05:00:00 EESTPress release

Shiseido Company, Limited (“Shiseido”) has agreed on Tuesday, September 17, 2019 to extend for a further six years its research alliance with the dermatological laboratory CBRC (Cutaneous Biology Research Center), established by Harvard Medical School Dermatology Research Labs, and Massachusetts General Hospital in Boston, Massachusetts, USA. This new agreement will be effective July 2021 through June 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917006201/en/ Shiseido’s President and CEO, M. Uotani, Executive Vice President, Y. Shimatani, CBRC Director, Dr. D.E.Fisher and President, MGH Dr. P. Slavin (Photo: Business Wire) The CBRC was founded in 1989, and is known as a world-class laboratory in the field of dermatology. Shiseido has been collaborating for 30 years with the CBRC as a pioneer of open innovation pursuing unprecedented research collaboration with external organizations both nationally and internation

Three Hospital Systems Earn Five-Star Ranking from Patient Safety Movement Foundation18.9.2019 01:00:00 EESTPress release

On the first World Patient Safety Day, the Patient Safety Movement Foundation (PSMF) announces that it has awarded Dignity Health, MedStar Health and the UPMC with its five-star ranking making commitments in alignment with PSMF’s 18 evidence-based Actionable Patient Safety Solutions (APSS). APSS include solutions designed to help hospitals eliminate preventable patient deaths. Preventable deaths are the third leading cause of death in the U.S. “More than 200,000 patients die from preventable hospital errors in the U.S., and 4.8 million across the globe. Those numbers are simply not acceptable but also unthinkable,” said Dr. David Mayer, PSMF CEO. “Our 5-Star ranking acknowledges the commitment these organizations have made to achieve ZERO preventable deaths. The leadership demonstrated by these leaders is a model others can follow in instituting best practices in patient care.” Dignity Health is the largest hospital provider in California with 39 hospitals, and part of the newly formed

Amazon Studios Announces New Zealand as Location for Its Upcoming Series Based on The Lord of the Rings18.9.2019 01:00:00 EESTPress release

(NASDAQ: AMZN)—Amazon Studios announced today that its series based on J.R.R. Tolkien’s iconic fantasy novels The Lord of the Rings will shoot in New Zealand. Pre-production has started, and production on the series will begin in Auckland in the coming months. “As we searched for the location in which we could bring to life the primordial beauty of the Second Age of Middle-earth, we knew we needed to find somewhere majestic, with pristine coasts, forests, and mountains, that also is a home to world-class sets, studios, and highly skilled and experienced craftspeople and other staff. And we’re happy that we are now able to officially confirm New Zealand as our home for our series based on stories from J.R.R. Tolkien’s The Lord of the Rings,” said showrunners and executive producers J.D. Payne and Patrick McKay. “We are grateful to the people and the government of New Zealand and especially Auckland for supporting us during this pre-production phase. The abundant measure of Kiwi hospital

IFF-Lucas Meyer Cosmetics Acquires Speximo AB17.9.2019 23:15:00 EESTPress release

Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, and its affiliate, IFF-Lucas Meyer Cosmetics (IFF-LMC), have announced and completed the acquisition of Speximo AB, a Swedish technology company focused developing next generation stabilization and encapsulation products for use in the development of sustainable personal care and cosmetic products with potential multiple commercial application areas. Speximo’s patented technology was developed from research at the prestigious Lund University in Sweden. “It is critical that in our quest for innovation, we find products and technologies that align with and support our purpose – to redefine and transform how we live in and care for the resources of our world,” said Nicolas Mirzayantz, IFF Scent Division CEO. “With Speximo’s focus on sustainability, this acquisition fills that need and helps us support our customers’ efforts and consumer desire for products with a greener

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom